Hutchinson-Gilford Progeria Syndrome (HGPS) Market Forecast Report 2025 – Designed for Product & Growth Teams
This report is designed for companies and decision-makers seeking actionable insights on market size, growth, trends, and competitive strategies to drive expansion and success in the Hutchinson-Gilford Progeria Syndrome (HGPS) industry.
What is the current market size of the hutchinson-gilford progeria syndrome (hgps) industry, and what growth rate is it expected to achieve?
The hutchinson-gilford progeria syndrome (HGPS) market size has grown strongly in recent years. It will grow from $97.63 billion in 2024 to $106.56 billion in 2025 at a compound annual growth rate (CAGR) of 9.1%. The growth in the historic period can be attributed to the rise in awareness about rare genetic disorders, increasing in funding for progeria research, expansion of genetic testing, rise in government initiatives for rare disease, and rise in global prevalence of genetic disorders.
The hutchinson-gilford progeria syndrome (HGPS) market size is expected to see strong growth in the next few years. It will grow to $149.22 billion in 2029 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to an increase in funding for research and development of new therapies, rising prevalence of progeria, increasing global healthcare expenditure, rising adoption of novel therapeutic approaches, and growing demand for early diagnosis. Major trends in the forecast period include technological advancements, development of targeted therapies, advancements in next-generation sequencing (NGS) technologies, development of biomarkers, and advancements in drug delivery systems.
Download Your Free Sample PDF:
What are the major drivers contributing to the growth of the hutchinson-gilford progeria syndrome (hgps) market?
The increase in funding for research and development of new therapies is expected to propel the growth of the hutchinson-gilford progeria syndrome (HGPS) market going forward. Funding for Research and Development refers to financial resources allocated to innovate, improve, and advance scientific knowledge and technological solutions. An increase in funding for research and development is attributed to factors such as rising demand for innovative treatments and government support for healthcare advancements. Increased funding for research and development accelerates the advancement of treatments for hutchinson-gilford Progeria Syndrome by supporting clinical trials and fostering innovative therapies. It drives progress in understanding the genetic origins of the condition and facilitates the development of targeted solutions. For instance, in April 2024, according to the Office for National Statistics, a UK-based government agency, in 2022, the UK government's net expenditure on research and development (R&D) increased by 10.5%, rising to £15.5 billion ($17.59) from £14.0 billion ($15.88) in 2021. Therefore, the increase in funding for research and development of new therapies is driving the growth of the hutchinson-gilford progeria syndrome (HGPS) market.
What are the major market segments driving the growth of the hutchinson-gilford progeria syndrome (hgps) industry?
The hutchinson-gilford progeria syndrome (HGPS) market covered in this report is segmented –
1) By Treatment Type: Farnesyltransferase Inhibitors (Zokinvy (Lonafarnib)), Low-dose Aspirin, Physical And Occupational Therapy, Hearing Aids, Genetic Counseling, Other Treatment Types
2) By Route Of Administration: Oral, Injectable, Intravenous, Transdermal
3) By Mechanism Of Action: Antisense Oligonucleotides, Crispr-cas9 Gene Editing, Rna Interference, Targeted Drug Delivery Systems
4) By End-User: Hospitals, Specialty Clinics, Academic And Research Institutes, Other End-Users
Subsegments:
1) By Farnesyltransferase Inhibitors (Zokinvy (Lonafarnib)): Monotherapy With Lonafarnib, Combination Therapy With Other Drugs
2) By Low-dose Aspirin: Cardiovascular Protection, Anti-inflammatory Therapy
3) By Physical And Occupational Therapy: Mobility Support And Rehabilitation, Joint And Bone Health Management, Adaptive Equipment For Daily Activities
4) By Hearing Aids: Conventional Hearing Aids, Bone-Anchored Hearing Aids (BAHA), Cochlear Implants
5) By Genetic Counseling: Family Genetic Testing, Genetic Risk Assessment, Prenatal Counseling And Guidance
6) By Other Treatment Types: Stem Cell Therapy, Gene Editing and Therapy, Nutritional Support And Management
View The Full Market Report:
What are the top market trends driving innovation in the hutchinson-gilford progeria syndrome (hgps) industry?
Major companies operating in the hutchinson-gilford progeria syndrome (HGPS) market are focusing on developing advanced farnesyltransferase inhibitors to improve treatment efficacy and slow disease progression in affected patients. Farnesyltransferase inhibitors refer to drugs that block farnesyltransferase, an enzyme involved in protein modification, preventing abnormal cell growth and aging. For instance, in July 2022, Eiger BioPharmaceuticals, a US-based biopharmaceutical company, received European Commission-granted marketing authorization for Zokinvy as the first and only treatment approved in Europe for hutchinson-gilford progeria syndrome (HGPS) and processing-deficient progeroid laminopathies (PL) in children and young adults. Zokinvy, an oral disease-modifying agent, was shown in clinical trials to lower the risk of death in children by 72% and extend life by an average of 4.3 years. The European Commission's centralized marketing authorization is valid in all 27 EU member states as well as Iceland, Liechtenstein, and Norway.
Who are the key market players contributing to the growth of the hutchinson-gilford progeria syndrome (hgps) industry?
Major companies operating in the hutchinson-gilford progeria syndrome (HGPS) market are National Institutes of Health (NIH), Mount Sinai, Johns Hopkins Hospital, Duke University, Mayo Foundation for Medical Education and Research, Cleveland Clinic, Children's Hospital of Philadelphia, St. Jude Children's Research Hospital, Cincinnati Children's Hospital Medical Center, University of Maryland, Boston Children's Hospital, Children’s Hospital Los Angeles, Harvard Medical School, The Scripps Research Institute, Blueprint Genetics, Medicover Hospitals, Sentynl Therapeutics, UCSF Helen Diller Family Comprehensive Cancer Center, Progeria Research Foundation, AnGes MG Inc., PRG Science & Technology Co. Ltd.
Which regions are leading the growth of the hutchinson-gilford progeria syndrome (hgps) market globally?
North America was the largest region in the hutchinson-gilford progeria syndrome (HGPS) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hutchinson-gilford progeria syndrome (HGPS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Hutchinson-Gilford Progeria Syndrome (HGPS) Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
Need Customized Data On Hutchinson-Gilford Progeria Syndrome (HGPS) Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you're entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: The Business Research Company | LinkedIn
Comments
Post a Comment